Clinical trial
Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir…
NCT00116636 · Therapeutic Concepts, Other · Completed
Key facts
| NCT number | NCT00116636 |
|---|---|
| Title | Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) in HIV Positive Adult Patients |
| Official title | A Phase II, Open Label, Single Arm Study of the 48-Week Virologic and Immunologic Response to Lopinavir/Ritonavir (Kaletra) as a Single Agent in a Cohort of HIV Positive Adult Patients |
| Lead sponsor | Therapeutic Concepts, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Kaletra |
| Enrollment | 40 |
| Start date | Jun 1, 2005 |
| Completion | Dec 1, 2007 |
| First posted | Jun 30, 2005 |
| Last update posted | May 1, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: